TP53 and small cell lung carcinoma: However, the ability to reveal TP53 mutations or other possible SCLC‐associated genomic signatures in plasma would provide additional insight into possible resistance mechanisms that are particularly important in individuals that show no evidence of T790M or other known resistance mechanisms, and may justify the need for a re‐biopsy to confirm the histological transformation.